IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer’s disease by regulating cGAS lactylation
Year: 2026
Type: article
Abstract: Microglia-mediated neuroinflammation, considered one of the most plausible pathogenic hypotheses underlying Alzheimer’s disease (AD), plays a pivotal role in the initiation and progression of this devastating condition. Recently, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated promising neuroprotective effects in both preclinical and clinical studies. Previously, we developed an orally-administered GLP-1RA peptide called OHP2, which is capable of crossing the blood-brain barrier for the treatment of AD. OHP2 has been shown to effectively reduce brain inflammation in AD mouse models. In this study, we discovered that OHP2 treatment induced IL-27 secretion from astrocytes and modulated microglial reprogramming from the neurotoxic M1 phenotype to the neuroprotective M2 phenotype through glycolysis/cGAS lactylation clock/mTOR pathway, thereby alleviating excessive neuroinflammation. These findings provide a rationale for further pharmacological investigations into OHP2 and suggest that IL-27 may hold significant implications for AD therapy as a metabolic regulator. Oral GLP-1RA OHP2 has the potential to treat Alzheimer’s disease (AD) by promoting the reprogramming of microglia via enhancing the secretion of IL-27 from astrocytes. IL-27, acting as a metabolic regulator, can induce the reprogramming of microglia and may treat AD. OHP2 and IL-27 regulate the reprogramming of microglia from the M1 type to the M2 type via the glycolysis/cGAS lactylation clock/mTOR pathway.
Source: Journal of Neuroinflammation
Authors: Yixuan Du, Lingxi Wu, Yang Mao, Song Chen, Xiangdong Gao
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,090
Awards: G6081498644, G6879468387
OpenAlex ID: W7123355024